Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of VX-809 to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of VX-809 in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR Gene Mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
- 27 Jun 2014 New trial record